Semaglutide Shows Superior Weight Loss Compared to Resmetirom in MASH Patients

Real-world data presented at AASLD's Liver Meeting 2026 indicates that semaglutide 2.4 mg leads to significantly greater weight loss than resmetirom in adults with MASH (metabolic dysfunction-associated steatohepatitis). A retrospective analysis of over 2,800 patients on semaglutide showed an average weight loss of 18.9 lbs at six months, compared to 5.6 lbs in the resmetirom group. A separate study also highlighted substantial weight and ALT reductions with semaglutide compared to untreated MASH patients.